Trials / Completed
CompletedNCT00093093
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 900 (planned)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.
Detailed description
Compare the efficacy and safety of viramidine 600 mg twice a day (BID) versus ribavirin 1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2a to treatment-naive patients with chronic hepatitis C (CHC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Viramidine | |
| DRUG | Ribavirin | |
| DRUG | pegylated interferon alfa-2a |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2004-10-04
- Last updated
- 2012-06-22
Locations
100 sites across 12 countries: United States, Argentina, Australia, Canada, France, Israel, Italy, Poland, Puerto Rico, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00093093. Inclusion in this directory is not an endorsement.